Cytokinetics Just Sued Bristol Myers Over a Drug It Helped Create

Cytokinetics also demanded a jury trial on any triable issues. They're not tiptoeing around this.

The strategic logic is clear: MYQORZO hit U.S. pharmacies in January 2026. It's gaining commercial traction. The last thing Cytokinetics needs is a patent cloud hanging over its launch, scaring off doctors, payers, and partners. Filing this suit is essentially a preemptive strike, getting out ahead of any potential infringement action from BMS.

A $1 Billion Market With Room for Two (Maybe)

This fight matters because the cardiac myosin inhibitor market isn't some niche backwater. Depending on how you slice the numbers, the HCM therapeutics market sits somewhere between $593 million and $1.48 billion in 2026. And cardiac myosin inhibitors are the fastest-growing drug class within it.

Right now, the competitive landscape is basically a two-horse race. BMS has Camzyos. Cytokinetics has MYQORZO. Both drugs carry a REMS requirement (a special safety monitoring program) because of the risk of heart failure from too much suppression of heart function. Both are approved for symptomatic obstructive HCM.

It's a duopoly, and duopolies tend to get messy. When two players control an entire drug class, every competitive advantage matters: pricing, physician relationships, clinical data, label expansions. And intellectual property. Especially intellectual property.

If BMS could successfully assert its patent against MYQORZO, it could theoretically restrict Cytokinetics' commercial freedom. That's the nightmare scenario for Cytokinetics investors, and exactly why the company went on offense.

Wall Street Isn't Sweating (Yet)

Analysts reacted to the lawsuit with something between a shrug and a thumbs-up for Cytokinetics. H.C. Wainwright reiterated a Buy rating with a $140 price target, saying it doesn't expect the litigation to affect MYQORZO's commercial momentum. Barclays raised its target to $110 from $95, citing strong MYQORZO sales that beat estimates. Citizens bumped its target to $110 from $105.

The consensus? This is Cytokinetics playing defense to protect a successful launch, not a sign that something is going wrong.

That said, patent litigation is inherently unpredictable. Delaware patent cases can drag on for years, and outcomes swing on highly technical claim construction arguments that even experienced patent attorneys can't predict with confidence. The market is pricing in a favorable outcome for Cytokinetics right now, but courts don't always cooperate with analyst models.

Why This Could Reshape the Whole Drug Class

Zoom out for a second. Cardiac myosin inhibitors are still a young drug class. Cytokinetics isn't just defending MYQORZO; it's also developing CK-586, another cardiac myosin inhibitor aimed at heart failure with preserved ejection fraction (a different type of heart failure). The company's pipeline strategy depends on freedom to operate in this therapeutic space.

If BMS's patent holds up, it could cast a shadow over not just MYQORZO but future cardiac myosin programs too. That would give BMS a kind of toll-booth position in the drug class: anyone who wants to develop a cardiac myosin inhibitor for HCM might need to navigate around BMS's intellectual property.

Conversely, if Cytokinetics wins and the patent is invalidated, BMS loses a potential competitive weapon and the playing field stays open. For patients, that's probably the better outcome; competition tends to drive both innovation and access.

The Bottom Line

This lawsuit is about more than two companies arguing over a patent number. It's about who gets to own the future of a billion-dollar drug class that's still in its early innings. Cytokinetics built MYQORZO from the ground up and doesn't intend to let a late-arriving patent claim get in the way. BMS, sitting on a broadly approved global franchise with Camzyos, has its own interests to protect.

The case will play out in a Delaware courtroom over months (probably years). But the real verdict will show up in prescription volumes, market share, and whether Cytokinetics can keep building momentum without legal distractions. For now, the company is betting that the best defense is a very public, very aggressive offense.

When the FDA Commissioner Tries to Kill a Drug Himself

Reports claim FDA Commissioner Marty Makary personally tried to block KalVista's rare disease drug, an almost unprecedented intervention that raises uncomfortable questions about political influence at the agency. The drug got approved anyway, but the fallout is just beginning.